Late morfofunctional alterations of the Sertoli cell caused by doxorubicin administered to prepubertal rats by Otávio Brilhante et al.
Brilhante et al. Reproductive Biology and Endocrinology 2012, 10:79
http://www.rbej.com/content/10/1/79RESEARCH Open AccessLate morfofunctional alterations of the Sertoli cell
caused by doxorubicin administered to
prepubertal rats
Otávio Brilhante1, Fatima K Okada2, Estela Sasso-Cerri3, Taiza Stumpp2* and Sandra M Miraglia2Abstract
Background: Doxorubicin is a potent chemotherapeutic drug used against a variety of cancers. It acts through
interaction with polymerases and topoisomerase II and free radical production. Doxorubicin activity is not specific
to cancer cells and can also damage healthy cells, especially those undergoing rapid proliferation, such as
spermatogonia. In previous studies our group showed that etoposide, another topoisomarese II poison, causes
irreversible damage to Sertoli cells. Thus, the aim of this study was to address the effects of doxorubicin on Sertoli
cell morphology and function and on the seminiferous epithelium cycle when administered to prepubertal rats.
Methods: Prepubertal rats received the dose of 5 mg/Kg of doxorubicin, which was fractioned in two doses:
3 mg/Kg at 15dpp and 2 mg/Kg at 22dpp. The testes were collected at 40, 64 and 127dpp, fixed in Bouin’s liquid
and submitted to transferrin immunolabeling for Sertoli cell function analysis. Sertoli cell morphology and the
frequency of the stages of the seminiferous epithelium cycle were analyzed in PAS +H-stained sections.
Results: The rats treated with doxorubicin showed reduction of transferrin labeling in the seminiferous epithelium
at 40 and 64dpp, suggesting that Sertoli cell function is altered in these rats. All doxorubicin-treated rats showed
sloughing and morphological alterations of Sertoli cells. The frequency of the stages of the seminiferous epithelium
cycle was also affected in all doxorubicin-treated rats.
Conclusions and discussion: These data show that doxorubicin administration during prepuberty causes
functional and morphological late damage to Sertoli cells; such damage is secondary to the germ cell primary
injury and contributed to enhance the spermatogenic harm caused by this drug. However, additional studies are
required to clarify if there is also a direct effect of doxorubicin on Sertoli cells producing a primary damage on
these cells.
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Doxorubicin is an anthracyclic antibiotic with potent
chemotherapeutic activity against a variety of cancers.
The toxicity of this drug is mediated by its interaction
with topoisomerase II, an enzyme that is abundant in
cells undergoing rapid and constant proliferation. Doxo-
rubicin toxicity can also be mediated by the generation
of free radicals [1,2] and lipid peroxidation [3]. Both
mechanisms are not specific to cancer cells and can* Correspondence: taiza.stumpp@gmail.com
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reproduction in any medium, provided the ordamage healthy cells [4-7]. In the testis, spermatogonia
are the main doxorubicin target, as observed after etopo-
side treatment, because of their intense and continuous
proliferative activity [8]. The administration of doxorubi-
cin to prepubertal rats causes damage to spermatogonia
[9] and irreversible damages to adult spermatogenesis
[9,10]. Extensive injuries such as decrease of spermato-
gonia, degeneration and/or decrease of early spermato-
cytes, vacuolated seminiferous epithelium, reduction of
epididymis cauda sperm count and sperm motility,
which were caused by a single dose of doxorubicin
(10 mg/Kg bw), have been characterized in the rat
testicular tissue after the schedule’s termination [11].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and etoposide [14-16], another topoisomerase-interacting
drug, also cause damage to germ cells, especially when
administered during prepubertal and peripubertal phases.
In previous studies our group showed that etoposide ad-
ministration to prepubertal rats causes irreversible damage
to Sertoli cells [17,18], leading to severe spermatogenesis
impairment.
Sertoli cells play a key role in spermatogenesis control
and germ cell development [19,20] and are pivotal for
testicular homeostasis; this phenomenon is maintained
through the complex interactions with germ cells and
with the other testicular somatic cells, such as Leydig
and myoid cells [21]. Sertoli cell alterations can cause se-
vere damage to spermatogenesis [22-24]. Some Sertoli
cell toxicants, such as 2,5-Hexanedione [25] and Mono-
(2-ethylhexyl) Phthalate [26], have been shown to cause
massive germ cell death. On the other hand, germ cell
death can also lead to functional and morphological altera-
tions of Sertoli cells [27]. Because Sertoli cells are consid-
ered the most resistant cell in the testis, most of the
alterations caused to these cells by the administration of dif-
ferent toxicants are considered to be secondary effects of
germ cell death [28,29]. However, previous studies have
suggested that germ cell death caused by etoposide admin-
istration to prepubertal rats is not the unique factor respon-
sible for the damages observed in Sertoli cells, since even
after seminiferous epithelium recovery, Sertoli cells still
showed functional and morphological alterations [17,18].
The transferrin is vital to the regulation of spermatogenesis.
It has been demonstrated that transferrin constitutes 5% of
all proteins secreted by Sertoli cell [30]. In addition, it is a
reliable instrument of investigation of the Sertoli cell func-
tion, both in vitro and in vivo [31,32] and it has been con-
sidered one of the best markers for this scope [33].
Consequently, transferrin has been largely utilized for the
evaluation of the Sertoli cell function and its labeling has
been successfully included in studies that aimed to investi-
gate the possible functional alterations produced as a re-
sponse to harmful events [34,35]. Germ cells also express
transferrin receptors [36]. Therefore, transferrin labeling
was utilized in the current study.
The studies performed by our group have suggested
that prepubertal testes are more sensitive to chemother-
apeutic drugs than adult testes [9,15,16]. Doxorubicin is
largely used in child cancer treatments and has been
shown to be very aggressive to germ cells. However, the
effects of doxorubicin administration on the morphology
and function of Sertoli cells have not been detailedly
addressed yet, especially during prepuberty. Thus, the
aim of the present study was to evaluate the effects of
doxorubicin on Sertoli cell function and morphology
when administered to prepubertal rats during key peri-
ods of testicular and Sertoli cell development.Methods
Animals and drug administration
Sixty male Wistar rats (Rattus norvegicus albinus) were
maintained under 12/12 hr light/dark cycles, at 21-23°C
room temperature; standardized lab chow (Nuvilab CR1,
NuvitalW, Curitiba, PR, Brazil) and water were provided
ad libitum. The protocol regarding animal care and
treatment was approved by the Ethical Committee for
Animal Research of the Federal University of São Paulo,
Brazil (reference number: 0559/08).
The animals were distributed into two major groups:
control (C) and doxorubicin-treated (D). The rats from
group D received 5 mg/Kg of doxorubicin (RubidoxW,
Bergamo – São Paulo, Brazil) by intraperitoneal route.
This dose was fractioned into two doses: one of 3 mg/Kg
that was administered at 15 days postpartum (dpp) and
one of 2 mg/Kg that was administered at 22dpp. The
rats from the control group received 0.9% saline solution
at the same ages and volume administered to the
doxorubicin-treated group. The rats were maintained
under standard conditions of luminosity (12 hr light/
12 hr dark) and temperature (22-23°C). Food and water
were allowed ad libitum.
The C and D groups were subdivided into three sub-
groups of 10 rats each, according to the ages of euthanasia:
40dpp (subgroups C40 and D40); 64dpp (subgroups C64
and D64) and 127dpp (subgroups C127 and D127). These
ages were chosen because they represent key time points
of spermatogenesis development, i.e., at 40dpp the rats are
considered peripubertal [13], at 64dpp they have already
reached puberty [37] but are not sexually mature and at
127dpp they are adults [14] and sexually mature [38].
Testis collection and analysis
At the ages previously specified, the rats were weighed
and submitted to euthanasia through CO2 inhalation
according to recommendations of the Ethical Committee
of the Federal University of Sao Paulo (UNIFESP). The
testes were removed, weighed and had their volume mea-
sured according to the Scherle’s method [39]. Subse-
quently, the testes were immersion-fixed in Bouin’s liquid
for 48 hr. Each testis was transversally cut and one half
was embedded in Paraplast PlusW with DMSO (Sigma)
and the other half was paraffin-embedded. From the frag-
ments embedded in Paraplast PlusW, 3μm cross-sections
were obtained and submitted to the Periodic Acid-Schiff
histochemical method (PAS) and counterstained with
Harris’s Hematoxilin (H). From the paraffin-embedded
fragments, 7μm cross-sections were obtained and submit-
ted to the transferrin immunolabeling, as described below.
Transferrin immunolabeling
The sections obtained from the paraffin blocks were
dewaxed, washed in running tap water for Bouin’s
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15 minutes. The slides were washed in phosphate buffer
(PBS, pH 7.2) and incubated with 7% BSA for 15 min-
utes. The slides were then incubated with the primary
antibody anti-transferrin (1:1000, ICN Aurora, Ohio,
USA) for 1 hr, washed in PBS and incubated with the
secondary antibody (LSABW, Dako, California, USA) for
30 minutes. After that, the slides were washed in PBS
and incubated with Streptavidin-Peroxidase (LSABW,
Dako, California, USA) for 30 minutes. The reaction was
revealed with DAB (DAKO, California, USA) andFigure 1 Testicular cross-sections of 40 day-old control (1A) and doxo
method. The Figure 1A shows seminiferous epithelium presenting normal
located close to the basal membrane of the seminiferous epithelium (inset
depletion is observed. Figure 1C depicts a detached portion of seminiferou
Figure 1D shows Sertoli cell nuclei into the tubular lumen (arrows).counterstained with Harris’s Haematoxylin. Negative
control slides were performed by incubating the sections
with non-immune serum.
Stereology
To investigate transferrin production by Sertoli cells, the
volume density (Vv) of transferrin-positive tissue in the
seminiferous epithelium and in the interstitial tissue was
obtained through the ratio between the positive tissue in
each of these compartments and the total testicular tis-
sue analyzed [17]. These measurements were obtainedrubicin-treated (1B-1D) rats submitted to PAS+H histochemical
morphology. The nuclei of Sertoli cells show evident nucleoli and are
; arrowheads). In the Figure 1B, a tubular section showing germ cell
s epithelium in which Sertoli cell nuclei are observed (arrows). The
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England) with a x20 objective lens.
Histopathological analysis and frequency of the stages of
the seminiferous epithelium cycle
For the histopathological analysis, the testicular sections
from the Paraplast blocks were totally analyzed and the
alterations, especially the Sertoli cell alterations, were
described.
The frequencies of the stages of the seminiferous epi-
thelium cycle were obtained from Parablast-embedded
testes and the analysis was performed according to Hess
et al. [40]. Two hundred seminiferous tubule cross-
sections were analyzed per rat, which is the minimum
number of sections that must be analyzed when the
number of animals per group is 10 (n = 10) [32]. The
identification of the stages of the seminiferous epithe-
lium cycle was based on the classification of Leblond
and Clermont [41]. The frequency of the stages, in
percentage, was calculated by the ratio between the
number of sections in each stage and the total num-
ber of analyzed sections multiplying by 100 [42].
Because the stages II and III as well as the stages XII
and XIII are very similar between each other, they
were grouped according to previously described
[43-45]. This analysis was performed under a light
microscope using x50 and x100 objective lenses.
Statistical analysis
The data were submitted to t test. The results were con-
sidered significant when p ≤ 0.05.
Results
Testicular histopathology
The histopathological analysis of the testes (Figures 1, 2
and 3) showed that the control rats presented normal
morphology of seminiferous epithelium and of Sertoli
cells at 40 (Figure 1A), 64 (Figure 2A) and 127
(Figure 3A) days of age. The rats treated with doxorubi-
cin showed seminiferous epithelium vacuolization
(Figure 3B) and germ cell depletion (Figures 1B, 2B and
3B–D). These alterations appeared at all ages, but be-
came more intense at 64 days. Sertoli cell also showed
morphological alterations in all doxorubicin-treated rats.
Their nuclei showed abnormal morphology (Figures 2C
and 3B–C) and some of them were distant from the
basal membrane (Figures 1C, 2B, 3B) or even in the
tubular lumen (Figures 1D and 2B–C). Eventually, Ser-
toli cell only tubular sections were observed (Figure 2B).
The rats from D64 and D127 subgroups showed intense
disorganization of the seminiferous epithelium and elon-
gated spermatid retention at stage IX of the seminiferous
epithelium cycle (Figure 2D). The rats from D127 sub-
group showed partial recovery of spermatogenesis.Transferrin labeling and Sertoli cell function
Transferrin labeling observed in the seminiferous epithe-
lium (Figures 4, 5 and 6) was dependent on the treat-
ment (doxorubicin or saline solution) applied, on the
euthanasia age and on the stage of the seminiferous epi-
thelium cycle. The rats from C40 (Figure 4A) and D40
(Figures 4B-C) subgroups showed few labeled regions in
the seminiferous epithelium. In the C40 subgroup, few
Sertoli cells showed weak labeling in the cytoplasm
(Figure 4A); however, cells in the basal region of semin-
iferous tubules, probably spermatogonia, showed intense
labeling (Figure 4A). The D40 subgroup showed trans-
ferrin labeling in the Sertoli cells, but no labeling in the
spermatogonia were observed (Figure 4B). Some hypo-
trophic tubular sections from D40 rats did not show any
transferrin labeling (Figure 4C). On the other hand, C64
(Figure 5A) and C127 (Figure 6A) control subgroups
showed strong and abundant labeling in the seminifer-
ous epithelium. In these subgroups, Sertoli cells
(Figures 5A, 6A) and elongated spermatids (Figure 6A)
showed intense labeling. In both C64 and C127 sub-
groups, transferrin labeling was more abundant in stages
II-III/XIV (Figure 5A) and VII (Figure 6A), respectively.
In the D64 subgroup, some tubular sections in stages II-
III and VII showed weak labeling in the Sertoli cell cyto-
plasm and no labeling in the nucleus (Figure 5B). In the
seminiferous tubules with intense germ cell depletion,
no transferrin labeling was observed (Figure 5C). In the
D127 subgroup, intense transferrin labeling was
observed in the Sertoli cell cytoplasm and in some germ
cells located in the basal region of the seminiferous epi-
thelium (Figure 6B), as observed in the C127 subgroup
(Figure 6A); however, at the stage VII of seminiferous
epithelium, the labeling seemed to be less abundant in
the D127 subgroup than in the C127 subgroup (Figures
6A–B). In this subgroup (C127), transferrin labeling was
observed either in the cytoplasm or nucleus of Sertoli
cells (Figure 6A), while in D127, these cells showed only
cytoplasm immunolabeling. Moreover, in some elon-
gated spermatids, the strong transferrin labeling was also
more abundant in C127 (Figure 6A) than in D127
(Figure 6B). In the D127 subgroup, some tubular sec-
tions with intense germ cell depletion showed rare trans-
ferrin immunolabeling (Figure 6C–D).
The pattern of transferrin labeling (i.e., the stages in
which transferrin labeling was observed and the cell
types that were labeled) in the doxorubicin-treated rats
was similar to that observed in the control rats. How-
ever, the volume density of transferrin-positive total tes-
ticular tissue reduced in the D40 subgroup (Figure 7)
when compared to C40 subgroup, whereas in D64 and
D127 this parameter was not altered in comparison to
the corresponding control subgroups C64 and C127. On
the other hand, in the D40 and D64 subgroups, the
Figure 2 Testicular cross-sections of 64 day-old control (Figure 2A) and doxorubicin-treated (Figures 2B-D) rats submitted to the
PAS+H method. The Figure 2A depicts part of a tubular section containing Sertoli cell nuclei with normal morphology. These nuclei are located
close to the basal membrane (arrows) of the seminiferous epithelium and show evident nucleolus (inset; arrowhead). In the Figure 2B, a Sertoli
cell only tubular section is observed. In this tubular section, one of the Sertoli cell nuclei is far from the basal membrane (arrowhead) and another
is sloughed into the tubular lumen (arrow). The Figure 2C depicts a sloughed portion of seminiferous epithelium (arrowheads) into the tubular
lumen in which a Sertoli cell nucleus can be seen (arrow). In the inset, this Sertoli cell nucleus with irregular profile shows abnormal clear areas
(arrow). Figure 2D shows a tubular section in stage IX of the seminiferous epithelium cycle with retention of step 19 spermatids (arrow). Note the
presence of intraepithelial spaces and free primary spermatocytes associated.
Brilhante et al. Reproductive Biology and Endocrinology 2012, 10:79 Page 5 of 16
http://www.rbej.com/content/10/1/79volume density of transferrin labeling in the semini-
ferous epithelium reduced when compared with the cor-
responding control subgroups C40 and C64 (Figure 8).
No significant alteration of the volume density of trans-
ferrin labeling in the seminiferous epithelium was
observed in the D127 subgroup in relation to C127 sub-
group (Figure 8). The labeling pattern in the interstitial
tissue was very similar in the control and doxorubicin-treated rats. Only the D64 subgroup showed volume
density reduction of the transferrin-positive interstitial
tissue (Figure 9).
Frequency of the stages of the seminiferous epithelium
cycle
The frequency of some stages of the seminiferous epi-
thelium cycle was altered in all doxorubicin-treated rats
Figure 3 Testicular cross-sections of 127 day-old control (Figure 3A) and doxorubicin-treated (Figures 3B-3D) rats submitted to the
PAS+H method. The Figure 3A depicts seminiferous tubule sections showing normal morphology. The Sertoli cells show normal nuclei (inset;
arrowheads). In the Figure 3B, tubular sections with severe germ cell depletion and intraepithelial vacuoles (thin arrows) are seen. A displaced
Sertoli cell nucleus from the basal membrane is also observed (thick arrow). Some Sertoli cell nuclei show abnormal profile (arrowheads). The
Figure 3C shows Sertoli cell nuclei with abnormal morphology, showing round shape (thick arrows); in one of them the nucleolus is not evident.
A binucleated formation of round spermatids can also be noted into the lumen (thin arrow). The Figure 3D depicts a portion of a seminiferous
tubule showing a clear area without germ cells (arrows) and many primary spermatocytes in the tubular lumen (asterisk).
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an increase of the frequency of stages I, XI and XIV and
a reduction of the frequency of stages II-III, IV, V and VI
were observed in the doxorubicin-treated rats (Figure 10)
when compared to the corresponding C40 subgroup. In
the D64 subgroup, an increase of the frequency of stages
II-III, VII and IX and a reduction of the frequency of
stages I and VIII were observed when compared with
the C64 subgroup (Figure 11). The D127 subgroupshowed partial recovery of the synchrony of the semin-
iferous epithelium cycle. In this subgroup only the fre-
quency of stage VII increased and the frequency of
stages XII-XIII decreased when compared with the C127
subgroup (Figure 12).
Discussion
The deleterious action of doxorubicin on male germ cells
has been described [9]. The citotoxity caused by
Figure 4 Testicular cross-sections of 40 day-old control (Figure 4A) and doxorubicin-treated (Figure 4B-C) rats submitted to transferrin
labeling. The Figure 4A shows weak transferrin labeling in the Sertoli cell cytoplasm (arrows) of the control rat and strongly transferrin-positive
germ cells, probably spermatogonia, which are located in the basis of the seminiferous epithelium (arrowheads). In the Figure 4B (doxorubicin-
treated rat), although Sertoli cell cytoplasm is positive (arrows), no labeling is observed in the spermatogonia (arrowheads). The Figure 4C depicts
a seminiferous tubule cross-section showing germ cell depletion and no transferrin labeling. Sertoli cell nucleus (arrow). Note the intense labeling
in the interstitial tissue (Figures 4A-C; asterisks).
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to its therapeutic activity; it interferes with molecules asso-
ciated to the nuclear DNA and with enzymes (RNA and
DNA polimerases, topoisomerases I and II) that are active
in the cell division process. Then, doxorubicin forms a
complex with chromatin [46], blocking the G2 phase of
the cell cycle [47,48] and provoking single and/or double
strand DNA breaks [49]. Doxorubicin also interferes with
membrane lipids [50-53], provoking alterations in their
chemical structure and impairing their function. The pro-
duction of reactive species of oxygen, as a consequence of
free radicals caused by doxorubicin, can also affect the cel-
lular functions, altering the cellular metabolism indifferent aspects [52,54]. In fact, the production of free
radicals is one of the factors that limit the therapy with
doxorubicin. This anticancer agent produces, as previously
mentioned, a significant increase of lipid peroxidation and
alterations of antioxidant enzyme activities in different
organs of rats, including testis, as observed in vitro [55]. It
provokes significant elevation in the testicular malondial-
dehyde concentrations and decreases of glutathione con-
tent, glutathione reductase (GR), glutathione-S-transferase
(GST), superoxide dismutase (SOD) and catalase activities,
thus indicating oxidative stress production in doxorubicin-
induced testicular toxicity [11]. Besides, the deleterious
effect of this anticancer agent on adult rat testis lipids and
Figure 5 Testicular cross-sections of 64 day-old control (Figure 5A) and doxorubicin-treated (Figure 5B-C) rats submitted to transferrin
labeling. In the Figure 5A (control rat), intense transferrin labeling is observed in the Sertoli cell cytoplasm (thin arrows) in both seminiferous
tubule sections (stages II-III and XIV). Sertoli cell nuclei (thick arrows) and elongated spermatids (arrowhead) are not labeled. The Figure 5B
(64 day-old doxorubicin-treated rat) shows very weak transferrin labeling in the Sertoli cell cytoplasm of tubules at stages II-III and VII (thick
arrow); however, no labeling is observed in the Sertoli cell nucleus (thin arrow). The Figure 5C depicts a seminiferous tubule cross-section
showing intense germ cell depletion in which no transferrin labeling is observed. Interstitial tissue immunolabeling is also noted (Figures 5A;
asterisks).
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regimes, resulting in a gradual loss of spermatogenesis and
in a decrease in phospholipids, including glycerophospholi-
pids and sphingomyelin; in this context, glycerophospholi-
pids selectively loose their major polyunsaturated fatty acid
(PUFA), while sphingomyelin looses its major very long-
chain PUFA (VLCPUFA). By contrast, triglycerides and
especially cholesterol esters (CE) tend to accumulate in the
testes undergoing germ cell death, probably in the surviv-
ing Sertoli cells. Their fatty acid patterns suggest that ini-
tially these lipids retained part of the PUFA coming from,or no longer used for the synthesis of germ cell glycero-
phospholipids. Determining whether this accumulation
results from a physiologic adaptation to the effects of
doxorubicin or simply reflects another lipid derangement
caused by the drug remains to be investigated [56].
Although some of the doxorubicin mechanisms of ac-
tion on germ cell are known, the effects of this drug on
other testicular components are poorly understood.
Spermatogonia are the preferential doxorubicin target
due to the presence of the enzyme topoisomerase II, but
probably primary spermatocytes can also be damaged,
Figure 6 Testicular cross-sections of 127 day-old control (Figure 6A) and doxorubicin-treated (Figure 6B-D) rats submitted to
transferrin labeling. The Figures 6A-B show intense transferrin labeling in the seminiferous epithelium (stage VII). However, in the Figure 6A
(control group), the labeling is more abundant than in the Figure 6B (doxorubicin-treated group). In the control group (Figure 6A), transferrin
labeling is observed in the Sertoli cell cytoplasm (thick arrow) and nucleus (inset, thin arrow) as well as in the elongated spermatids (arrowhead).
In the doxorubicin-treated group (Figure 6B) transferrin labeling is observed in the Sertoli cell cytoplasm (thick arrow) and in the elongated
spermatids (arrowhead), but not in the Sertoli cell nucleus (inset, thin arrow). The Figure 6C shows two seminiferous tubule cross-sections
containing large portions of sloughed seminiferous epithelium (stars). In one of them, transferrin positive Sertoli cell cytoplasm is observed
(arrow). In the Figure 6D, a tubular section with intense germ cell depletion shows weak Sertoli cell cytoplasm immunolabeling (thin arrows) and
no labeling in the Sertoli cell nucleus (arrowheads). Intraepithelial vacuole (thick arrow). Note the intense labeling in the interstitial tissue
(Figure 6A-D; asterisks).
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DNA synthesis, at determined stages, is more accentu-
ated than in pre-meiotic synthesis as observed after
etoposide-treatment [8]. Thus, DNA synthesis in pre-
meiotic spermatocytes is not so vulnerable to the doxo-
rubicin action as pre-mitotic DNA synthesis. Moreover,it is possible that other topoisomerases can be involved
in the process of pre-meiotic synthesis.
Thus, considering the different mechanisms of action
of doxorubicin previously mentioned, it is also possible
that additionally to spermatogonia, other cells, including
Sertoli cells, are also targeted by doxorubicin.
Figure 7 Volume density of transferrin-positive total testicular tissue (VvT) in the control and doxorubicin-treated rats. The VvT showed
significant reduction in the 40dpp doxorubicin-treated rats (*) when compared with the corresponding control subgroup. No alteration of this
parameter was observed in the 64 and 127dpp doxorubicin-treated rats.
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administration to rats at early prepubertal phase alters
transferrin production by Sertoli cells at specific phases
of testicular development, indicating a functional alter-
ation of these cells. On the other hand, transferrin
synthesis by Sertoli cells is dependent on the presence of
germ cells [28,30,57]. Thus, it is possible that the dimin-
ution of transferrin production by Sertoli cells is a con-
sequence of germ cell depletion caused by doxorubicin.
The significant recovery of transferrin synthesis by
Sertoli cells and of the seminiferous epithelium observed
in D127 subgroups support this hypothesis.
It is important to highlight that doxorubicin reduces the
synthesis of the transferrin receptor and leads to atypical
changes in intracellular iron distribution and trafficking
[58]. In the testes, transferrin receptors are present in the
basal region of the Sertoli cell membrane and are essential
to promote iron transportation from blood to the germFigure 8 Volume density of transferrin-positive seminiferous epitheliu
reduction of this parameter was observed in the doxorubicin-treated rats a
subgroups. The 127dpp doxorubicin-treated rats showed an important recocells that are localized in the adluminal compartment of
the seminiferous epithelium. Iron is crucial for germ cell
proliferation and differentiation and Sertoli cells are the
only way by which this ion can reach the germ cells at the
adluminal compartment. To deliver iron ions to these
cells, diferric plasma transferrin is endocytosed through
the receptor at the basal region of the Sertoli cell mem-
brane. In the cytoplasm of the Sertoli cells, iron is
detached from plasma transferrin, captured by Sertoli cell
transferrin and delivered to germ cells [59]. Thus, if trans-
ferrin receptors are damaged by doxorubicin, the iron traf-
fic through the seminiferous epithelium could have been
affected. In addition, the germ cells localized in the basal
compartment of the seminiferous epithelium get iron
directly from plasma transferrin [60]. Thus, damages to
transferrin receptors could also cause reduction of iron
capture by these cells. Indeed, in the D40 subgroup,
spermatogonia were negative for transferrin, what maym (VvES) in the control and doxorubicin-treated rats. A significant
t 40 and 64dpp (*) when compared with the corresponding control
very of the VvES.
Figure 9 Volume density of transferrin-positive interstitial tissue (VvTi) in the control and doxorubicin-treated rats. Only the 64dpp
doxorubicin-treated rats showed an increase of the VvTi (*) when compared with the control subgroup. Although the 40dpp doxorubicin-treated rats
have shown a smaller mean value of this parameter and the 127dpp rats have shown a higher mean value of VvTi, these data were not significant.
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transferrin-positive seminiferous epithelium.
In addition to transferrin receptor alterations, doxorubi-
cin also increases the plasmatic levels of transferrin [61].
Since most of the transferrin present in the interstitial tis-
sue comes from the blood stream, it could be possible that
the increase in the volume density of transferrin-labeled
interstitial tissue observed in the D64 subgroup was a
result of an increase of plasmatic transferrin levels. How-
ever, it does not seem to be the case, since the total
volume of the interstitial tissue also increased. Moreover,
the volume density of transferrin-positive interstitial tissue
of D40 and D127 subgroups was normal, indicating that
transferrin of this testicular compartment was notFigure 10 Frequency of the stages of the seminiferous epithelium cyc
and XIV and a decrease of the frequency of stages II to VI were observed a
asterisk (*).affected. This suggests that, in the testis, doxorubicin
acted specifically on Sertoli cell transferrin.
Although the damages to Sertoli cell function are gen-
erally reversible, the morphological alterations observed
after doxorubicin treatment suggest that these cells may
have been directly injured in addition to their secondary
damage occurred due to the germ cell primary harm.
The presence of Sertoli cell nuclei in the tubular lumen,
for example, indicates that the structural integrity of
these cells was affected by the treatment with doxorubi-
cin. Dislocation of Sertoli cell nuclei from basal to
adluminal or luminal compartments has also been
demonstrated in adult rats treated with cimetidine
[62,63]. In these studies, this alteration was associated tole in the 40-day-old rats. An increase in the frequency of stages I, XI
t this age. Statistically significant alterations are indicated by the
Figure 11 Frequency of the stages of the seminiferous epithelium cycle in the 64-day-old rats. At this age, the frequency of the stages I
and VIII decreased whereas stages II-III, VII and IX showed an increase of their frequencies. Statistically significant alterations are indicated by the
asterisk (*).
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http://www.rbej.com/content/10/1/79Sertoli cell death. Morevover, in another research, reduc-
tion of Sertoli cell number followed by a decrease in
sperm production, normal morphology and motility was
observed in doxorubicin-treated adult mice, 6 weeks
after the end of the treatment [64]. In the present study,
although we did not score the Sertoli cell number, the
Sertoli cell nuclei detached into the lumen indicate that
these cells may have been drastically injured. Thus, be-
sides the secondary Sertoli cell damage, due to the pri-
marily occurred germ cell death, it is also important to
consider that when doxorubicin was administered,
Sertoli cells were passing through critical phases of their
development, what makes a primary damage more likely
to occur. Around 15dpp, when the rats received the first
dose of doxorubicin, Sertoli cells stop to proliferate [65]
and the blood-testis barrier start to be formed [66,67].
At 22dpp, when the second dose was administered, Ser-
toli cells were still undergoing maturation [65,68].
Therefore, we could also consider the higher susceptibil-
ity of Sertoli to doxorubicin at these phases than adultFigure 12 Frequency of the stages of the seminiferous epithelium cyc
increase of its frequency and the stages XII-XII showed a decrease of its fre
asterisk (*).Sertoli cells. Because Sertoli cells are crucial for sperm-
atogenesis, damages in these cells at early pubertal phase
could also lead to germ cell death in other later periods
of sexual maturation as peripuberty (40 days) and after
the completion of puberty (64 days). Hence, considering
the Sertoli cell morphological alterations observed in
this study, it is possible that the seminiferous epithelium
alterations observed in the doxorubicin-treated rats
could also be consequence of direct Sertoli cell damage.
Indeed, some alterations such as intraepithelial vacuoli-
zation, spermatid retention and high frequency of Sertoli
cell nuclei in which the nucleolus was not evident sug-
gest that Sertoli cells were damaged independently of
germ cell death. Moreover, despite the possibility of the
decrease of Sertoli cell transferrin labeling a conse-
quence of germ cell depletion, it is important to consider
that doxorubicin can increase the production of free
radicals as previously observed [52,54]. In addition, pri-
mary immature Sertoli cell obtained from 18-day-old rat
testes and cultured with the anticancer agents cis-le in the 127-day-old rats. At this age, the stage VII showed an
quency. Statistically significant alterations are indicated by the
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http://www.rbej.com/content/10/1/79diamminedichloroplatinum (CDDP), adriamycin and
vinblastin revealed that these agents have direct dam-
aging effects on rat Sertoli cell, decreasing the level of
transferrin. In this research, the concentration of trans-
ferrin in the culture medium was measured and used as
an indicative of Sertoli cell function [69]. The role of
Sertoli cell in postchemotherapy azoospermia has also
been noticed in a 31-year-old patient who underwent
cancer cytotoxic chemotherapy for non-Hodgkin's
lymphoma at 13 years of age . In this patient, a fraction
of Sertoli cells (13%) in the atrophic tubules re-
expressed the intermediate CK-18 filament protein,
which is normally absent after puberty, but not the
D2-40 antigen, a membrane-linked glycoprotein which
loss of expression at puberty marks an irreversible step
in Sertoli cell maturation. The reversion to a dedifferen-
tiated state, marked by the reexpression of CK-18 as a
consequence of chemotherapy, besides the partial inacti-
vation of Sertoli cells following the chemotherapeutic
drug cytotoxicity may contribute to the spermatogenic
impairment, then resulting in infertility [70]. Although
testicular germ cell products can regulate Sertoli cell
function [71,72] and alter the production of transferrin,
for example, it is also possible that a harmful effect of
doxorubicin on Sertoli cell might have occurred in the
present study. Disruption of Sertoli cell structure and
shedding of immature germ cells have been observed in
doxorubicin-treated adult mice [64]. However, other
experiments using labeling of house-keeping proteins
such as actin and/or markers of Sertoli cell differenti-
ation as cytokeratin-18 must be conducted to better
clarify this subject. Another relevant hypothesis is that
the blood-testis barrier injury, caused by doxorubicin
toxicity, was mediated by the generation of free radicals
[1,2] and lipid peroxidation [3]. In fact, studies in the
testis and other organs have illustrated the role of envir-
onmental toxicant-induced oxidative stress in mediating
the disruption of cell junctions, which is regulated by
the activation of phosphatidylinositol 3-kinase (PI3K)/c-
Src/focal adhesion kinase (FAK) and mitogen-activated
protein kinase (MAPK), signaling pathways involving po-
larity proteins and leading to reproductive dysfunction,
such as reduced sperm count and semen quality in men
[73]. However, the impact of doxorubicin toxicity on in-
tegrity and damage of the blood-testis barrier during
prepuberty are still to be established.
Important alterations were observed in the frequency
of the seminiferous epithelium cycle after doxorubicin
treatment, especially at 64dpp. The seminiferous epithe-
lium cycle is a strictly controlled process that is charac-
terized by specific germ cell associations, defined as
stages of the seminiferous epithelium cycle. During this
cycle, Sertoli cells change their morphology and func-
tion, according to the requirements of the spermatogenicprocess. Because Sertoli cells are responsible for the
synchronization of the seminiferous epithelium cycle,
alterations of these cells can cause problems to the pro-
gression of the stages during the cycle. It is also import-
ant to consider that the massive loss of germ cells
disturbs the typical cell association of each stage, leading
to alterations of the frequency of the stages of the semin-
iferous epithelium cycle. Another important factor that
should be considered is that postpubertal and adult
doxorubicin-treated rats showed retention of step 19
spermatids. At this step, these cells are released into the
tubular lumen through a process called spermiation,
which occurs at stage VIII of the seminiferous epithelium
cycle. This process is controlled by Sertoli cells [74] and
injuries to these cells can alter spermiation and cause
spermatid retention [75].
Alterations of the seminiferous epithelium cycle has
been described after administration of chemicals such as
1, 3 dinitrobenzene [75] and 2, 5 hexanedione [76],
which are referred as Sertoli cell toxicants [77,78]. In
general, chemotherapeutic drugs are not considered Ser-
toli cell toxicants. However, previous studies by our
group have suggested that etoposide, another che-
motherapeutic drug, in addition to causing damage to
the germ cells, may also provoke direct damages to Ser-
toli cells [17,18]. The present study also points to a pos-
sible effect of doxorubicin on Sertoli cells. Indeed, some
Sertoli cell alterations suggest that these cell damages
are more severe than those considered be exclusively
secondary effects resulted from germ cell death.
Another important aspect is that the stage-specific gene
expression is a fundamental characteristic of rat spermato-
genesis and Sertoli cells [79]. In fact, in adult doxorubicin-
treated mice, a quantitative RT-PCR analysis showed a
dysregulation in the expression of some genes such as Csk
and Axl, which are important to the remodeling of semin-
iferous tubule during spermatogenesis and to the germ
cell differentiation respectively [64]. These remarks could
support some of our observations, concerning the con-
spicuous alterations in the frequency of some seminiferous
epithelium stages in doxorubicin-treated rats, in all ages
investigated (40, 64 and 127 days). In addition, the inacti-
vation and delay of the Sertoli cell maturation due to cyto-
toxicity of the chemotherapeutic drugs may contribute to
the spermatogenic impairment [70] and could be related
to the functional alterations of the Sertoli cell, and prob-
ably to the changes in seminiferous epithelium cycle as
well. In our report, the delay or interruption of the Sertoli
cell differentiation could justify, at least in part, the signifi-
cant increase of the frequency of stage I and the reduction
of subsequent stages such as II -III, IV, V, VI at 40 days, in
comparison to the control rats. In addition, it has been
shown that the aforementioned stages II and III are infre-
quently pinpointed as being especially vulnerable to agents
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http://www.rbej.com/content/10/1/79that act on spermatogenesis [80]; therefore, it is possible
that their frequencies have been altered due to doxorubi-
cin direct action on Sertoli cells. Moreover, as previously
mentioned, it is important to remember that doxorubicin
was administered during prepubertal phase, when the
Sertoli cells were still undergoing maturation.
Summarizing, doxorubicin is a very potent drug that
acts through different mechanisms of action. Without
doubt, a secondary damage of Sertoli cell occurred due to
the injury caused to the germ cells. On the other hand, the
alterations observed in the present study, along with the
fact that Sertoli cells were not completely mature when
doxorubicin was administered, suggest that the direct
damage to the Sertoli cell observed is likely to be also
responsible, at least in part, for some of the testicular
alterations noticed. The iron atypical chelator action of
doxorubicin, which provokes the decrease of transferrin
receptor synthesis, leading to atypical changes in intracel-
lular iron distribution and trafficking [58], can also alter
the synthesis of trasferrin by the Sertoli cell, a
phenomenon that should also be considered.
Measurements of transferrin contents in rat testes can
indicate damage to Sertoli cell function. High doses of
cisplatin (8 mg/kg), for example, affect testicular trans-
ferrin concentration, but lower doses (4 mg/kg and
2 mg/kg) have no significant effect on Sertoli cell func-
tion. Thus, an anti-cancer agent primarily may affect the
DNA synthesizing activity of spermatogonia and sper-
matocytes, but high doses of these agents have deleteri-
ous effects on Sertoli cells [81]. The age of treatment
chosen can also be a determining factor in the type of
testicular damage observed. However, detailed studies
will be necessary to verify the direct damage of Sertoli
cell by the anticancer agent doxorubicin when adminis-
tered in early prepubertal rats.Conclusions
The evaluation of harmful action of chemotherapeutic
drugs on Sertoli cell during prepuberty is advisable since,
at this phase, Sertoli cells play a pivotal role on spermato-
genesis, supplying the factors required for germ cell gener-
ation and helping to synchronize the development of
germ cells at different stages of seminiferous epithelium.
These studies can also contribute to a better understand-
ing of the side effects of chemotherapeutic drugs upon the
prepubertal testis and upon the male fertility, contributing
to the development of chemotherapy protocols intending
germ cell protection. Besides, the relationship between the
delay in Sertoli cell differentiation or its dedifferentiation
with anticancer agents must be scrutinized.Competing interests
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